The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.
Source link
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound
Date:
More like thisRelated
French voters head to the polls in municipal runoffs with Paris, Marseille and Lyon in focus
PARIS -- French voters are returning to the polls...
New Hampshire wedding venue floor collapses; 6 hospitalized
The New Hampshire State Fire Marshal says six people...